Author

Erika P. Hamilton

Observed names: Hamilton Erika, Hamilton, Erika P.

Institutions: Sarah Cannon, Tennessee Oncology

Observed institutions: Sarah Cannon, Tennessee Oncology

OpenAlex ID: A5137101573

Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study

2026 · Shanu Modi, Rashmi K. Murthy, et al. · Clinical Breast Cancer · 1

ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from ER+/HER2− breast cancer.

2026 · Nuhad K. Ibrahim, Eva Maria Ciruelos, et al. · Journal of Clinical Oncology · 1

Tucatinib (TUC) combined with trastuzumab and pertuzumab (HP) as first-line (1L) maintenance therapy for HER2+ metastatic breast cancer (MBC): An in-depth safety analysis of HER2CLIMB-05.

2026 · Veronique C. Dieras, Giuseppe Curigliano, et al. · Journal of Clinical Oncology · 1

A phase 1/2 study of EP0062 (vosilasarm), a first-in-class oral selective androgen receptor modulator (SARM), in combination with standard-of-care endocrine therapy +/- targeted therapies in patients with advanced or metastatic AR+/ER+/HER2− breast cancer.

2026 · Rafael Grochot, Hyo S. Han, et al. · Journal of Clinical Oncology

Phase 1/2 study of CLIO-8221, a HER2-targeted, dual-payload exatecan and ATR inhibitor antibody-drug conjugate (ADC) in patients with advanced HER2-expressing solid tumors.

2026 · Timothy A. Yap, Charlotte Rose Lemech, et al. · Journal of Clinical Oncology

Efficacy and safety of tucatinib (TUC) vs placebo (PBO) combined with trastuzumab and pertuzumab (HP) as maintenance therapy for HER2+ metastatic breast cancer by stratified subgroups.

2026 · Erika P. Hamilton, Giuseppe Curigliano, et al. · Journal of Clinical Oncology

Trastuzumab deruxtecan (T-DXd) + durvalumab (D) in patients (pts) with previously untreated HER2+ unresectable/metastatic breast cancer (mBC): Final analysis from DESTINY-Breast07.

2026 · Sherene Loi, Erika P. Hamilton, et al. · Journal of Clinical Oncology

Patient-reported outcomes from the adjuvant ado-trastuzumab emtansine (T-DM1) for older patients with HER2+ breast cancer (ATOP) trial.

2026 · Kathryn Jean Ruddy, Brenda F. Ginos, et al. · Journal of Clinical Oncology

Elacestrant in combination with capivasertib in patients with ER+/HER2− advanced breast cancer: Update from ELEVATE, a phase 1b/2, open-label, umbrella study.

2026 · Wassim McHayleh, Sara M. Tolaney, et al. · Journal of Clinical Oncology

Long-term safety results and adverse event (AE) management recommendations in patients with ER+/HER2− metastatic breast cancer (mBC) receiving prifetrastat, a first-in-class KAT6 inhibitor, at the recommended phase 3 dose (RP3D) of 5 mg once-daily (QD).

2026 · Rachel M. Layman, Patricia LoRusso, et al. · Journal of Clinical Oncology

Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study

2023 · Nakamura Yoshiaki, Mizuno Nobumasa, et al. · Institutional Repositories DataBase (IRDB)

Works count: 13

Citation count: 3

H-index: 1

I10-index: